Hepatitis C Newsletters
DACLATASVIR / TMC435 /pegIFN / RBV
Bristol Myers-Squibb and Tibotec have agreed to work together to investigate the benefits of combining the NS5A inhibitor daclatasvir (BMS-790052) with the NS3 protease inhibitor, TMC435 in a Phase II trial expected to start in the first part of 2012. Researchers will be looking for SVR at 12 and 24 weeks post treatment in GT1 patients. There will be 3 once-a-day treatment arms: 1) daclatasvir/TMC435/pegIFN/ RBV; 2) daclatasvir/TMC435/RBV; or 3)
only daclatasvir/TMC435. Their goal is to find an all-oral treatment for hepatitis C....
MY EXPERIENCE WITH HEPATITIS C AND TREATMENT
gotoguy
On August 1st of 2007, I was informed that I had hepatitis C, and that I must have contracted it some 30+ years ago during my youth when I experimented with intravenous drug use. Knowing nothing about hepatitis C and thinking I had just been given a death sentence, I told my doctor that I thought that I was one of the lucky ones who survived those days but I guess I didn’t. It just took longer.
On the morning of August 1st, 2007, I was a 50 year old, happily married man with 3 great adult children. I had a great job and was working towards early retirement. On the evening of August 1st, 2007, I still had all these things, but I was thinking all my future plans evaporated.....
and more.....
GI & Hepatology News
GI & Hepatology News is published monthly and mailed to all U.S. members and available to all members online.
View Current Issue
(VOL. 6 • NO. 1 • JANUARY 2012)
In This Issue
Hepatitis C Deaths Now Exceed HIV
The Centers for Disease Control and Prevention is poised to recommend one-time screening of all “baby boomers” for hepatitis C virus, in part because deaths associated with this infection are now more common than HIV related deaths in the United States, CDC officials said.
Noncathartic CTCb Compared Well With Colonoscopy: Pros and Cons of Methods Balanced Out.
When members of the general population were offered colorectal cancer screening, 34% agreed to noncathartic computed tomographic colonography, whereas 22% agreed to have a colonoscopy, in a study published online in the Lancet Oncology.
TNF Blockers: FDA Advises Vigilance
The Food and Drug Administration has asked manufacturers of tumor necrosis factor blockers to enhance their follow-up of pediatric and young adult patients who develop malignancies while on these treatments.
HBV Screening, Prophylaxis Needed Before Chemotherapy
In cancer patients with hepatitis B virus infection, prophylaxis to prevent its reactivation during chemotherapy lowers mortality, however, screening for the virus remains uncommon, said researchers from M.D. Anderson Cancer Center in Houston.
Program to Accredit ACOs Launches
The National Committee on Quality Assurance has launched a program to accredit accountable care organizations. The program offers three levels of accreditation based on the readiness of the ACO.
NYC Hepatitis C Task Force
NYC Jan 2012 Viral Hep Newsletter
Click Here
CAP Hepatitis C Literature Review
Monthly Pubmed Review of the most relevant research on hepatitis C.
2011: Year in Review
Alan Franciscus, Editor-in-Chief
HealthWise: Telling Our Stories
Lucinda K. Porter, RN
HCV Snapshots
Lucinda K. Porter, RN
Brain Fog - It Really Is All in Your Head
C.D. Mazoff, PhD
No comments:
Post a Comment